401 related articles for article (PubMed ID: 28743428)
21. Institution-wide and Within-Patient Evolution of Daptomycin Susceptibility in Vancomycin-Resistant Enterococcus faecium Bloodstream Infections.
Woods RJ; Patel TS; Nagel JL; Newton DW; Read AF
Infect Control Hosp Epidemiol; 2018 Feb; 39(2):226-228. PubMed ID: 29331166
[TBL] [Abstract][Full Text] [Related]
22. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection.
Munoz-Price LS; Lolans K; Quinn JP
Clin Infect Dis; 2005 Aug; 41(4):565-6. PubMed ID: 16028170
[No Abstract] [Full Text] [Related]
23. Frequency of occurrence and daptomycin susceptibility rates of Gram-positive organisms causing bloodstream infections in cancer patients.
Sader HS; Fritsche TR; Jones RN
J Chemother; 2008 Oct; 20(5):570-6. PubMed ID: 19028618
[TBL] [Abstract][Full Text] [Related]
24. Assessing outcomes of adult oncology patients treated with linezolid versus daptomycin for bacteremia due to vancomycin-resistant Enterococcus.
Patel K; Kabir R; Ahmad S; Allen SL
J Oncol Pharm Pract; 2016 Apr; 22(2):212-8. PubMed ID: 25326010
[TBL] [Abstract][Full Text] [Related]
25. [Therapeutic perspectives of linezolid in the management of infections due to multiresistant Gram-positive pathogens].
Manfredi R
Recenti Prog Med; 2007 Mar; 98(3):143-54. PubMed ID: 17484159
[TBL] [Abstract][Full Text] [Related]
26. Clinical experience with daptomycin: bacteraemia and endocarditis.
Levine DP
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii35-39. PubMed ID: 18829724
[TBL] [Abstract][Full Text] [Related]
27. Daptomycin.
Heidary M; Khosravi AD; Khoshnood S; Nasiri MJ; Soleimani S; Goudarzi M
J Antimicrob Chemother; 2018 Jan; 73(1):1-11. PubMed ID: 29059358
[TBL] [Abstract][Full Text] [Related]
28. [Daptomycin therapy in patients with bacteremia].
Llinares P; Iribarren JA
Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():17-25. PubMed ID: 22541971
[TBL] [Abstract][Full Text] [Related]
29. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
Sader HS; Watters AA; Fritsche TR; Jones RN
BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
[TBL] [Abstract][Full Text] [Related]
30. Daptomycin: a new drug class for the treatment of Gram-positive infections.
Alder JD
Drugs Today (Barc); 2005 Feb; 41(2):81-90. PubMed ID: 15821781
[TBL] [Abstract][Full Text] [Related]
31. Combatting resistant enterococcal infections: a pharmacotherapy review.
Mercuro NJ; Davis SL; Zervos MJ; Herc ES
Expert Opin Pharmacother; 2018 Jun; 19(9):979-992. PubMed ID: 29877755
[TBL] [Abstract][Full Text] [Related]
32. Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin.
Nailor MD; Sobel JD
Infect Dis Clin North Am; 2009 Dec; 23(4):965-82, ix. PubMed ID: 19909893
[TBL] [Abstract][Full Text] [Related]
33. Treatment considerations in vancomycin-resistant enterococcal bacteremia: daptomycin or linezolid? A review.
Shukla BS; Gauthier TP; Correa R; Smith L; Abbo L
Int J Clin Pharm; 2013 Oct; 35(5):697-703. PubMed ID: 23893061
[TBL] [Abstract][Full Text] [Related]
34. Daptomycin use in neutropenic patients with documented gram-positive infections.
Rolston KV; Besece D; Lamp KC; Yoon M; McConnell SA; White P
Support Care Cancer; 2014 Jan; 22(1):7-14. PubMed ID: 23975231
[TBL] [Abstract][Full Text] [Related]
35. Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003-2009).
Sader HS; Farrell DJ; Jones RN
J Chemother; 2011 Aug; 23(4):200-6. PubMed ID: 21803696
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
Jensen KT; Schønheyder H; Pers C; Thomsen VF
APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
[TBL] [Abstract][Full Text] [Related]
37. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
Napolitano LM
Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
[TBL] [Abstract][Full Text] [Related]
38. Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci.
Cervera C; Castañeda X; Pericas JM; Del Río A; de la Maria CG; Mestres C; Falces C; Marco F; Moreno A; Miró JM
Int J Antimicrob Agents; 2011 Nov; 38(5):365-70. PubMed ID: 21420835
[TBL] [Abstract][Full Text] [Related]
39. Emergence of daptomycin-resistant VRE: experience of a single institution.
Kamboj M; Cohen N; Gilhuley K; Babady NE; Seo SK; Sepkowitz KA
Infect Control Hosp Epidemiol; 2011 Apr; 32(4):391-4. PubMed ID: 21460492
[TBL] [Abstract][Full Text] [Related]
40. [Pharmacoeconomic assessment of daptomycin as first-line therapy for bacteraemia and complicated skin and skin structure infections caused by gram-positive pathogens in Spain].
Grau S; Rebollo P; Cuervo J; Gil-Parrado S
Rev Esp Quimioter; 2011 Sep; 24(3):154-63. PubMed ID: 21947099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
